# iBiOME

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ibiome

- Industry: Biotechnology
- Headquarters: Hefei, China
- Website: www.ibiome.com
- Latest round: Angel (Dec 2, 2021)
- Investors on record: 1

## About

Founded in 2021 and based in Hefei, China, iBiOME operates as a pharmaceutical company that focuses on Enterobacter drugs. The R&D team consists of scientists from universities such as Yale University, Harvard Medical School, and University of Science and Technology of China. Richard Flavell, one of the members of iBiOME's consultant team, is the professor of Yale University and the founder of Yale Department of Immunology. In November 2023, it raised pre-series A funding.

iBiOME's main business is the development of intestinal bacteria drugs, and the immunotherapy of human intestinal microorganisms. It has 4 core platforms, which are bacterial library and editing platform, process development platform, precise detection platform, and functional screening platform. Its pipeline with include Immue metabolismIBOBO1 and DescriptionIBN101. It also develops clinical treatment solutions, such as metabolic diseases, antitumor, inflammatory bowel disease, autoimmune diseases.

The company will use the funding for microbial and metabolite drug discovery and development.

## Funding rounds

- Angel, Dec 2, 2021 — CD Capital

## Investors

- CD Capital — Angel